Targeting signal transduction as a strategy to treat inflammatory diseases
LAJ O'Neill - Nature reviews Drug discovery, 2006 - nature.com
Inflammatory diseases are a major burden on humanity, despite recent successes with
biopharmaceuticals. Lack of responsiveness and resistance to these drugs, delivery …
biopharmaceuticals. Lack of responsiveness and resistance to these drugs, delivery …
HER1/EGFR targeting: refining the strategy
R Perez-Soler - The oncologist, 2004 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to:
Differentiate between ligand-dependent and ligand-independent human epidermal growth …
Differentiate between ligand-dependent and ligand-independent human epidermal growth …
Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy …
JR Johnson, M Cohen, R Sridhara, YF Chen… - Clinical Cancer …, 2005 - AACR
Abstract Purpose: To describe the Food and Drug Administration (FDA) review and approval
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
of erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) for treatment of patients with locally …
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity
CH Chiu, CM Tsai, YM Chen, SC Chiang, JL Liou… - Lung cancer, 2005 - Elsevier
Gefitinib is active and well tolerated in patients with advanced non-small cell lung cancer
(NSCLC); however, its role in patients with brain metastases has not been clearly defined …
(NSCLC); however, its role in patients with brain metastases has not been clearly defined …
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer
R Perez-Soler - Clinical cancer research, 2004 - AACR
Erlotinib (Tarceva) is a reversible and highly specific inhibitor of epidermal growth factor
receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 …
receptor (EGFR) tyrosine kinase. Phase I studies established a fixed daily oral dose of 150 …
Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics
R Tibes, J Trent, R Kurzrock - Annu. Rev. Pharmacol. Toxicol., 2005 - annualreviews.org
▪ Abstract The clinical application of tyrosine kinase inhibitors for cancer treatment
represents a therapeutic breakthrough. The rationale for developing these compounds rests …
represents a therapeutic breakthrough. The rationale for developing these compounds rests …
Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)
WS Siegel-Lakhai, JH Beijnen, JHM Schellens - The oncologist, 2005 - academic.oup.com
The CME activity for this article is forthcoming. Access and take the CME test online and
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …
receive 1 hour of AMA PRA category 1 credit at CME. TheOncologist. com Gefitinib (Iressa®; …
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists
GA Silvestri, MP Rivera - Chest, 2005 - Elsevier
Lung cancer is the most common cause of cancer death. The vast majority of patients
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …
present with non-small cell lung cancer (NSCLC) in advanced inoperable stages. The …
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing …
Purpose: To determine if tumor regression following treatment with gefitinib correlates with
the presence of sensitizing mutations in epidermal growth factor receptor (EGFR). Patients …
the presence of sensitizing mutations in epidermal growth factor receptor (EGFR). Patients …
State of the art in therapy for non-small cell lung cancer
JJ Laskin, AB Sandler - Cancer investigation, 2005 - Taylor & Francis
The treatment of lung cancer has changed rapidly over the last few years and now more
than ever a multi-disciplinary approach is vital to patient care. Surgical resection remains the …
than ever a multi-disciplinary approach is vital to patient care. Surgical resection remains the …